獸醫再生醫學市場 - 按動物類型、產品類型、應用、最終用戶 - 全球預測

由於動物慢性疾病和骨科問題的盛行率不斷增加，2024年至2032年獸醫再生醫學市場的複合年成長率預計將達到9.9%。隨著寵物數量的增加，對先進獸醫解決方案的需求激增。據美國寵物產品協會稱，到 2022 年，68% 的美國家庭擁有寵物。這些療法可以改善寵物的生活品質並延長它們的壽命。

生物技術的進步和研發投資的增加也推動了市場的成長。研究機構、獸醫診所和製藥公司之間的合作正在開發有效的再生療法。例如，《獸醫科學雜誌》2023 年的一項研究強調，接受幹細胞療法治療的狗的骨關節炎症狀改善了 20%。監管部門對新療法的批准以及獸醫專業人員對再生醫學益處的認知不斷提高，有利於新療法的採用。個人化醫療和創新給藥系統的趨勢提高了治療效果和可及性，塑造了產業前景。

整個獸醫再生醫學行業根據動物類型、產品類型、應用、最終用戶和地區進行分類。

生物治療領域預計到 2032 年將實現強勁成長，這主要是由於這些治療方法的功效和創新性質。生物療法因其再生能力和治療各種動物疾病的潛力而被利用，例如肌肉骨骼損傷、傷口癒合和慢性發炎性疾病。這些療法利用人體的自​​然癒合過程，為傳統療法提供微創且高效的替代方案。越來越多的臨床證據支持生物療法的安全性和有效性，加上研發投資的不斷增加，正在推動生物療法在獸醫實踐中的採用。

由於寵物和牲畜中受傷和外科手術的發生率不斷增加，到 2032 年，創傷/傷口護理應用領域將佔據顯著的行業佔有率。幹細胞治療和富血小板血漿 (PRP) 等再生療法可加速癒合、減少發炎並最大限度地減少疤痕。這些先進的療法提供了比傳統療法更有效、侵入性更小的替代方案，從而改善動物的治療結果並加快恢復時間。獸醫和寵物主人越來越意識到再生醫學對創傷和傷口護理的好處，加上治療方法和產品可用性的不斷進步，正在推動這一領域的擴張。

亞太地區獸醫再生醫學市場預計到 2032 年將大幅成長。寵物主人和獸醫越來越意識到幹細胞治療和組織工程等再生療法的好處。此外，對獸醫醫療基礎設施的大量投資和可支配收入的增加使人們能夠更多地獲得這些創新療法。在學術機構和生物技術公司之間合作的支持下，該地區對研發的高度重視正在進一步加速在整個亞太地區引入新型動物再生醫學。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 慢性和退化性疾病的發生率上升
    • 再生醫學不斷進步
    • 增加研發投入和活動
    • 寵物擁有量和支出不斷成長
  • 產業陷阱與挑戰
    • 治療的不良反應
    • 監管挑戰
• 成長潛力分析
• 監管環境
• 未來市場趨勢
• 按國家/地區分類的寵物數量
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按動物類型，2021 - 2032 年

• 主要趨勢
• 伴侶動物
• 畜牧動物

第 6 章：市場估計與預測：按產品類型，2021 - 2032 年

• 主要趨勢
• 幹細胞治療
  • 自體
  • 同種異體
• 生物療法
  • 富血小板血漿 (PRP)
  • 生長因子
• 組織工程

第 7 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 骨科
• 創傷/傷口護理
• 其他應用

第 8 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

• 主要趨勢
• 獸醫院
• 獸醫診所
• 學術界及研究機構

第 9 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• Animal Cell Therapies, Inc.
• Ardent
• Bioceltix
• Boehringer Ingelheim International GmbH
• CTSL (Cell Therapy Sciences)
• Dechra
• Enso Discoveries
• Magellan Stem Cells
• Medrego
• Regeneus Ltd (Cambium Bio Ltd.)
• StemcellX
• VetStem, Inc.
• Zoetis Inc.

The veterinary regenerative medicine market is poised to record 9.9% CAGR during 2024-2032, due to the increasing prevalence of chronic ailments and orthopedic issues in animals. With pet ownership rising, the demand for advanced veterinary solutions has surged. According to the American Pet Products Association, 68% of U.S. households owned a pet in 2022. Regenerative medicine, including stem cell therapy and tissue engineering, offers treatments for conditions like osteoarthritis, tendon injuries, and cardiac diseases in animals. These therapies improve pets' quality of life and extend their lifespans.

Advancements in biotechnology and increased R&D investments are also driving the market growth. Collaborations between research institutions, veterinary clinics, and pharmaceutical companies are developing effective regenerative therapies. For instance, a 2023 study by the Journal of Veterinary Science highlighted a 20% improvement in osteoarthritis symptoms in dogs treated with stem cell therapy. Regulatory approvals for new treatments and growing awareness among veterinary professionals about regenerative medicine's benefits are favoring adoption. The trend towards personalized medicine and innovative delivery systems enhances treatment efficacy and accessibility, shaping the industry outlook.

The overall veterinary regenerative medicine industry is classified based on animal type, product type, application, end-user, and region.

The biological therapy segment is slated to record robust growth through 2032, primarily due to the efficacy and innovative nature of these treatments. Biological therapies are utilized for their regenerative capabilities and potential to treat a variety of animal conditions such as musculoskeletal injuries, wound healing, and chronic inflammatory diseases. These therapies leverage the body's natural healing processes, offering a minimally invasive and highly effective alternative to traditional treatments. The growing body of clinical evidence supporting the safety and effectiveness of biological therapies, along with rising investment in R&D, is driving their adoption in veterinary practices.

The trauma/wound care application segment will register notable industry share by 2032, due to the increasing prevalence of injuries and surgical procedures among pets and livestock. Regenerative therapies, such as stem cell treatments and platelet-rich plasma (PRP), accelerate healing, reduce inflammation, and minimize scarring. These advanced therapies provide a more effective and less invasive alternative to conventional treatments, leading to improved outcomes and faster recovery times for animals. The growing awareness among veterinarians and pet owners about the benefits of regenerative medicine for trauma and wound care, coupled with ongoing advancements in treatment methodologies and product availability, is driving the expansion of this segment.

Asia Pacific veterinary regenerative medicine market is poised for substantial growth through 2032. Increasing pet ownership, especially in urban areas, is contributing to a rising demand for advanced veterinary care solutions. There is growing awareness among pet owners and veterinarians about the benefits of regenerative therapies, such as stem cell treatments and tissue engineering. Additionally, significant investments in veterinary healthcare infrastructure and rising disposable incomes are enabling greater access to these innovative treatments. The region's strong focus on R&D, supported by collaborations between academic institutions and biotechnology firms, is further accelerating the introduction of novel regenerative medicine for animals across Asia Pacific.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic and degenerative conditions
    • 3.2.1.2 Growing advancement in regenerative medicine
    • 3.2.1.3 Increasing R&D investment and activities
    • 3.2.1.4 Growing pet ownership and spendings
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects of the treatment
    • 3.2.2.2 Regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Pet population, by country
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Companion animals
• 5.3 Livestock animals

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Stem cell therapy
  • 6.2.1 Autologous
  • 6.2.2 Allogeneic
• 6.3 Biological therapy
  • 6.3.1 Platelet-rich plasma (PRP)
  • 6.3.2 Growth factors
• 6.4 Tissue engineering

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Orthopedics
• 7.3 Trauma/ wound care
• 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals
• 8.3 Veterinary clinics
• 8.4 Academics and research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Animal Cell Therapies, Inc.
• 10.2 Ardent
• 10.3 Bioceltix
• 10.4 Boehringer Ingelheim International GmbH
• 10.5 CTSL (Cell Therapy Sciences)
• 10.6 Dechra
• 10.7 Enso Discoveries
• 10.8 Magellan Stem Cells
• 10.9 Medrego
• 10.10 Regeneus Ltd (Cambium Bio Ltd.)
• 10.11 StemcellX
• 10.12 VetStem, Inc.
• 10.13 Zoetis Inc.